OR WAIT null SECS
© 2021 MJH Life Sciences and Ophthalmology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Philadelphia-Acuity Pharmaceuticals has raised $2.4 million in its first institutional round of financing to fund pre-clinical studies of Cand5, being developed for treating age-related macular degeneration (AMD).